Cost Of Services - Molecular Profiling Services was the largest of Caris Life Sciences, Inc.’s 2 reported lines in fiscal 2025, at $766.72M — 94% of $812.03M.
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Cost Of Services - Molecular Profiling Services | $278.75M | $349.12M | $766.72M |
| Cost Of Services - Pharma Research & Development Services | $27.38M | $63.15M | $45.31M |
| Total | $306.13M | $412.26M | $812.03M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Caris Life Sciences, Inc. reported in this breakdown added up to $812.03M. That was up 97.0% from $412.26M in fiscal 2024. Cost Of Services - Molecular Profiling Services was the largest revenue line, at $766.72M or 94.4% of the total, followed by Cost Of Services - Pharma Research & Development Services ($45.31M, 5.6%).
Compared with fiscal 2024, Cost Of Services - Molecular Profiling Services grew the fastest, rising 119.6% to $766.72M. Cost Of Services - Pharma Research & Development Services fell the most, down 28.2% to $45.31M. Over fiscal 2023 to 2025, revenue across these revenue lines went from $306.13M to $812.03M, a compound annual growth rate of 62.9%. Cost Of Services - Molecular Profiling Services' share of the total rose from 91.1% to 94.4% over the same years.
This breakdown covers every fiscal year from 2023 to 2025, as reported in Caris Life Sciences, Inc.'s annual filings.
United States was the largest of Caris Life Sciences, Inc.’s 2 reported lines in fiscal 2025, at $801.39M — 99% of $812.03M.
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $293.41M | $401.84M | $801.39M |
| International | $12.72M | $10.42M | $10.64M |
| Total | $306.13M | $412.26M | $812.03M |
In fiscal 2025, which ended December 31, 2025, the 2 regions Caris Life Sciences, Inc. reported in this breakdown added up to $812.03M. That was up 97.0% from $412.26M in fiscal 2024. United States was the largest region, at $801.39M or 98.7% of the total, followed by International ($10.64M, 1.3%).
Over fiscal 2023 to 2025, revenue across these regions went from $306.13M to $812.03M, a compound annual growth rate of 62.9%. United States' share of the total rose from 95.8% to 98.7% over the same years.
This breakdown covers every fiscal year from 2023 to 2025, as reported in Caris Life Sciences, Inc.'s annual filings.
Caris Life Sciences, Inc. (CAI) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Cost Of Services - Molecular Profiling Services, with $766.72M or 94.4% of the total, followed by Cost Of Services - Pharma Research & Development Services at $45.31M (5.6%).
Cost Of Services - Molecular Profiling Services was Caris Life Sciences, Inc.'s largest revenue line in fiscal 2025, with $766.72M in revenue, 94.4% of the $812.03M reported across its 2 revenue lines.
United States was Caris Life Sciences, Inc.'s largest region in fiscal 2025, with $801.39M in revenue, 98.7% of the $812.03M reported across its 2 regions.
Of the Caris Life Sciences, Inc. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Cost Of Services - Molecular Profiling Services grew the fastest, rising 119.6% from $349.12M to $766.72M.
Every figure is taken from Caris Life Sciences, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2023 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.